|
A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients with AIDS Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients with AIDS conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients with AIDS Clinical research trials and A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients with AIDS health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients with AIDS. A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients with AIDS Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients with AIDS clinical trial. Subjects frequently get the best healthcare possible for their A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients with AIDS condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients with AIDS  A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients with AIDS
A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients with AIDS
For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: To determine the safety and efficacy of zidovudine (AZT) treatment combined with syngeneic or HLA identical allogeneic lymphocyte transfer in the presence of interleukin 2 (IL-2) as a treatment for AIDS. Patients with documented HIV viremia will be evaluated. Effects on virus replication, immune function, and clinical condition will be monitored with periodic virus cultures, estimates of lymphocyte type and numbers, cell surface markers, in vitro lymphocyte responses and frequent clinical evaluations.
Details:
Eligibility:
Study Type: Interventional, Treatment, Dose Comparison
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Co-existing Condition: Patients with the following are excluded: Lymphoma. Active central nervous system (CNS) infection by bacteria, varicella zoster virus, herpes simplex virus, or Cryptococcus neoformans. Any prior CNS infection due to Toxoplasma gondii. Any active life-threatening infection including Pneumocystis carinii pneumonia (PCP) (if prior PCP then pre-PCP arterial PO2 must be above 80), disseminated cryptococcosis (if there was a prior cryptococcosis infection the patient must have had a negative blood and cerebrospinal fluid (CSF) culture taken more than 6 weeks after the last antifungal therapy). Any prior mycobacterium avium-intracellulare isolation. Patients with the following conditions are excluded: Lymphoma. Active central nervous system (CNS) infection by bacteria, varicella zoster virus, herpes simplex virus, or Cryptococcus neoformans. Any prior CNS infection due to Toxoplasma gondii. Any active life-threatening infection including Pneumocystis carinii pneumonia (PCP) (if prior PCP then pre-PCP arterial PO2 must be above 80), disseminated cryptococcosis (if there was a prior cryptococcosis infection the patient must have had a negative blood and cerebrospinal fluid (CSF) culture taken more than 6 weeks after the last antifungal therapy). Any prior mycobacterium avium-intracellulare isolation. Patients accepted for allogenic cell transfer must meet the CDC criteria for AIDS. Those patients who meet the criteria only because of Kaposi's sarcoma must also have a history of generalized lymphadenopathy (CDC category III), neurologic disease (CDC category IV-B), or constitutional disease (CDC category IV-A). Patients may be accepted for syngeneic cell transfer even if they have not met the CDC AIDS criteria, provided they have had constitutional disease (CDC category IV-A) or a specified non-AIDS defining secondary infection (CDC category IV-C2). Patients must have a positive blood culture for the AIDS virus before the beginning of therapy. Patients must be skin test negative for PPD. Patients must have a life expectancy of at least 6 months and a Karnofsky status of 60 or above. Patients must sign an informed consent agreement. From eligible patients precedence will be given to those with identical twin donors, then to Minnesota residents. The first patient must have an identical twin donor. Among eligible Minnesota patients without identical twin donors, the order of enrollment will be determined by overall good health, the presence of Kaposi's sarcoma (which permits monitoring of response by measuring lesions) and/or the presence of cytomegalovirus (CMV) viremia (which permits monitoring of response by remission of CMV viremia).
Total Enrollment:
Location and Contact Information:
Glaxo Wellcome Inc
Research Triangle Park, North Carolina, 27709
United States
Additional Information:
Study ID Numbers: 014B; 27433-10
Study Start Date:
Record last reviewed: February 1995
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002285
Other Hiv Infections Studies:
1. Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults
2. A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma
3. A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients with AIDS Related Complex
4. A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients
5. Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection
Related Studies:
Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Research Triangle Park Clinical Trials
A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients with AIDS
|
|
|
|
|
|
|
|
